Il faut bien noter que:Cmous23 a écrit : 31 mars 2020, 21:43 Cette étude randomisée montre pourtant que l’hydroxychloroquine améliore le pronostic.
"This article is a preprint and has not been certified by peer review [...]. It reports new medical research that has yet to be evaluated and so should not be used to guide clinical practice."
Pas le temps de l'analyser, je vais me fier au résumé:
"Findings
There were 2 patients showing mild secondary effects of HCQ treatment. More importantly, while 4 patients in the control group progressed to severe disease, none progressed in the treatment group.
[...]
Overall, it appears that HCQ treatment of patients with mild COVID-19 has a modest effect on clinical recovery (symptom relief on average 1 day earlier) but may be more potent in reducing the progression from mild to severe disease.
Study Limitations
This study is limited in its inclusion of only patients with mild disease, and exclusion of those on any treatment other than the standard of care. It would also have been important to include the laboratory values of positive RT-PCR detection of SARS-CoV-2 to compare the baseline and evolution of the patients’ viral load."
Merci, c'est intéressant malgré les conditionnels et les limites. ä semble plus sérieux que ce qu'a produit l'équipe de Raoult mais reste encore préliminaire. Pourquoi ne pas l'avoir amené dans votre message précédent?
Je note quand même que vos critères fluctuent: parfois, le traitement de Raoult est celui qui demande HCQ + azithromycine, parfois pas.
Jean-François